Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 84

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4
Chunk 84
---
.11%25%20from%202024%20to%202033.
                                                                                                                                                                                                                                                               7
                  https://www.globenewswire.com/news-release/2025/01/23/3014051/0/en/Irritable-Bowel-Syndrome-Treatment-Global-Market-Report-2024-2034-Development-of-New-Treatments-Emphasis-on-Personalized-Medicine-and-Emerging-Markets-Boosting-Growth.html
8https://www.globenewswire.com/news-release/2024/01/29/2818585/28124/en/Global-Inflammatory-Bowel-Disease-Treatment-Market-Set-to-Soar-with-Predicted-5-84-CAGR-by-2034.html#:~:text=The%20study%20cited%20an%20estimated,IBD%20(Inflammatory%20Bowel%20Disease)

AMR (antimicrobial resistance)
 

◾                        Clostridium Difficile Infection (CDI) – The U.S. Centers for Disease Control and Prevention                     
                     in a report titled “Antibiotic Resistance Threats In The United States” published in December 20199,                
    which is not incorporated by reference herein, has identified CDI as one of the most urgent antibiotic-resistant bacterial threats in
    the United States. CDI is most often caused by the use of broad-spectrum antibiotics which induce dysbiosis of the microbiome causing
    susceptibility to infection by C. difficile, a spore forming bacterium. It is the most common cause of hospital acquired infection in
                                                              the United States.                                                         
-----------------------------------------------------------------------------------------------------------------------------------------

◾            According to “Antibiotic Resistance Threats In The United States” a report published by U.S. Centers for Disease Control        
    and Prevention in December 2019, which is not incorporated by reference herein, CDI is responsible for the deaths of approximately 13,000
      Americans each year. Based on this report, the incidence of CDI in the U.S. was estimated to be 223,900 cases in hospitalized patients 
               in 2017. According to an article titled “Clostridium Difficile Infection Treatment Market Outlook (2024 – 2034)” 10,          
      which is not incorporated herein by reference, the global CDI treatment market size was set to reach $1.24 billion by the end of 2024